| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8531487 | International Immunopharmacology | 2018 | 7 Pages |
Abstract
Plumbagin was found to significantly inhibit the proliferation and invasion of L9981 and NL9980 cells, and may be an effective therapy for LCLC through targeting the IL-6/STAT3 signaling pathway.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Tao Yu, Yan-Yan Xu, Ying-Ying Zhang, Kai-Yu Li, Yi Shao, Gang Liu,